• Entecavir is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with histological evidence of active inflammation and/or fibrosis.
• Currently in Turkey, the reimbursement of antivirals is based on stratification of patients' viral load. Patients with very high viral load (HBV DNA level>10^7 copies/mL) are eligible to receive potent antivirals such as entecavir or tenofovir. Lamivudine is the first line treatment for patients with HBV DNA levels between 10^4 to 10^7 copies/mL. Treatment with lamivudine is known to be associated with high levels of resistance i.e. up to 69% of patients within 5 years of initiating therapy with lamivudine 1 . For LVD refractory patients Turkish reimbursement guidelines recommend switching to ADV monotherapy. Objective
• To evaluate the cost-effectiveness of entecavir (ETV) vs. lamivudine (LVD) in the treatment of nucleoside-naive chronic hepatitis B (CHB) patients and vs. adefovir (ADV) in LVD refractory CHB patients in Turkey, from the perspective of the Turkish Social Security Institution (Payers perspective).
Methods

Model Overview
• An existing deterministic cost-effectiveness model, simulating CHB progression, was adapted to fit the Turkish clinical setting (Figure 1 ).
• The model projects, as a function of serum HBV DNA level, the number of complications (compensated cirrhosis, decompensated cirrhosis and hepatocarcinomas), over a period of 10 years following the initiation of antiviral treatment. The relative risk data on liver complications used in the model were derived from the REVEAL study 2 .
• The model estimates lifetime survival, quality adjusted life years (QALYs) and overall disease costs for CHB patients receiving either ETV, LVD or ADV therapy in different patient groups.
• Therapeutic success rates (% of patients with levels of undetectable viral load) and resistance rates were used to determine patients prognosis. These data were derived from the RCT of ETV versus LVD 3, 4 in treatment-naïve patients. For the comparisons of ETV versus ADV in LVD refractory patients, the sources of information for ETV were used and combined with data from clinical trials of ADV in similar populations.
• Primary model outcome was incremental cost per QALY.
Efficacy Data
• Information on the distribution of patients across different levels of HBV DNA viral load in populations treated with ETV, LVD or ADV (Table 1 ) was based on results from randomized, controlled international clinical trials.
Results
•Treatment of 1.000 patients with ETV compared to LVD or ADV would result in a reduction of CHB related complications of 95 to 124 (Table 3 ).
•Over 10 years, ETV is associated with a QALY gain of 0.55 to 1.53 QALYs and with LYS of 0.66 to 0.68 years in Turkey (Table 4 ).
•Sensitivity analyses demonstrated the robustness of the estimate of dominance of ETV vs ADV and costeffectiveness ratios below 2-3 times GDP per QALY of ETV vs LVD in most scenarios. 
Limitations
•Due to lack of evidence, transition probabilities were based on indirect comparison and long-term extrapolation of epidemiological data. The influence of these input parameters on the results was thoroughly investigated in sensitivity analyses.
•In absence of long-term head to head evidence, modelling techniques provide the next best method of quantifying cost and benefits of new medical technologies. However, up to 6 years real life data with ETV confirms the efficacy, safety and rare occurrence of resistance as observed in pivotal trials
•Cost of liver transplantation is not included in this model, which underestimates the benefits of ETV vs. LVD since potent viral suppression coupled with very low resistance profile of ETV is estimated to prevent progression to disease stages requiring liver transplantation. • Due to lack of specific utility data for Turkish patients, published data were obtained from an international utility study 5 , in which CHB without complications was established as 0.77; compensated cirrhosis as 0.8; decompensated cirrhosis as 0.35 and hepatocarcinoma as 0.41.
• Disease costs (expressed in 2010 Turkish Liras) were derived from a Turkish cost of CHB disease study 6 and the Turkish drug price list (Table 2) . 7
• Life expectency data was estimated using gender and age-specific life expectencies for Turkish population. 8 Table 1 : Efficacy parameters at 48 weeks • Both costs and effects were discounted at 3% annually.
Sensitivity Analyses
• Sensitivity analyses were performed to investigate the robustness of the results.
• In the sensitivity analysis the following input parameters were varied within their uncertainty distributions: relative risk of suffering a complication for specific levels of viral load, disease costs and resistance rates. 
Conclusions
• WHO cost effectiveness criterion defines treatments as highly cost effective when their cost/QALY is below 2-3 times local GDP • This analysis suggest entecavir, relative to lamivudine is a highly cost-effective option in treating naïve CHB patients in Turkey • In lamivudine refractory patients, treatment with entecavir is a cost saving option relative to adefovir. 
